Study information The study involves about 2000 men and women between the ages of 18 to 55(inclusive) years,from several countries. Laquinimod is a new oral drug that was developed for the treatment of Multiple Sclerosis.It was developed from a parent compound,which caused serios side effects,including inflammation of the delicate membranes around the lungs,heart and abdominal organs(serositis),and heart attacs(myocardial infaction).
お気に入りの翻訳
